23 Valent Pneumococcal Polysaccharide Vaccine Market

Request Discount

23 Valent Pneumococcal Polysaccharide Vaccine Market (Type - Pre-filled Syringe, and Single Dose Vial; Age Group - 2-10 Years, 10-64 Years, and 64+ Years; Distribution - Hospitals, Clinics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

  • Published : February, 2022

  • Rep Id : HC08735

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the 23 valent pneumococcal polysaccharide vaccine market provides an in-depth analysis of segments and sub-segments in the global as well as regional 23 valent pneumococcal polysaccharide vaccine market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional 23 valent pneumococcal polysaccharide vaccine market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global 23 valent pneumococcal polysaccharide vaccine market. According to the report, the global 23 valent pneumococcal polysaccharide vaccine market is projected to reach USD 3333 million by 2027 from USD 1946 million in 2021, growing with a CAGR of 9% over the forecast period of 2021-2027.

 

Market Insight

23 Valent Pneumococcal Polysaccharide Vaccine is used for protection against types of diseases caused due to the pneumococcal bacteria including pneumonia a type of lung infection. Other infections caused due to pneumococcal bacteria are Meningitis, sinus infection, ear infection, bacteremia, and others. A 23 valent pneumococcal polysaccharide vaccine provides protection from 23 different types of bacteria causing pneumococcal disease. People who smoke cigarettes and people above 65 years of age with specific medical conditions are at high risk of getting pneumococcal infections. Most of the time pneumococcal infections are mild and if not treated can be fatal to the patient. 23 Valent Pneumococcal Polysaccharide vaccine only needs one shot. Also, it is recommended for the age group 65 and above as well as for children over 2 years of age having a high risk of pneumococcal disease.

 

The growing adult population over age 65 or the geriatric population is majorly driving the growth of the market. According to the United Nations, there were 703 million people 65 years of age and above in 2019 and the number is expected to reach 1.5 billion by 2050. People above 65 years of age who are at high risk of pneumococcal disease or infection are recommended by doctors, and health experts to get vaccinated with pneumococcal vaccine even if they are vaccinated before the age of 65. Growing accessibility to healthcare facilities is also driving the growth of the market. Hospitals and clinics are a major center for accessing the 23 Valent Pneumococcal Polysaccharide Vaccine. An increase in the accessibility to these healthcare facilities would mean increased access to the vaccine. Thus, increasing its demand. Getting a vaccine approved in countries around the world is a herculean task. Adding to this difficulty there are stringent government regulations for the approval of vaccines owing to the sensitivity of the trials. Thus, these stringent government regulations may hamper the growth of the market. Nevertheless, new opportunities are expected to arise as new technological advancements are taking place in terms of production techniques, supply chain, and others.

 

The 23 Valent Pneumococcal Polysaccharide Vaccine market is regionally categorized into North America, Asia-Pacific, Europe, and RoW. North America is expected to dominate the market over the forecast period. 23 Valent Pneumococcal Polysaccharide Vaccine is mostly currently available in higher-income countries of which countries in North America form a significant part. Advanced healthcare infrastructure facilitating the easy distribution of vaccines combined with matured pharmaceutical production base and an aging population with active demand for the vaccine is increasing the scope of the market in North America.

 


23 Valent Pneumococcal Polysaccharide Vaccine Market


Segment Covered

The report on the global 23 valent pneumococcal polysaccharide vaccine market covers segments such as type, age group, and distribution. On the basis of type, the sub-markets include pre-filled syringe, and single dose vial. On the basis of age group, the sub-markets include 2-10 years, 10-64 years, and 64+ years. On the basis of distribution, the sub-markets include hospitals, clinics, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Merck & Co., Inc., GlaxoSmithKline plc, Walvax Biotechnology Co, Chongqing Zhifei Biological Products Co Ltd, Sinovac Biotech Ltd., Chengdu Institute of Biological Products Co., Ltd., and Others.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the 23 valent pneumococcal polysaccharide vaccine market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount